ClinicalTrials.gg
RecruitingNCT06948591Updated Oct 23, 2026

BioBrace® Augmentation in Anterior Cruciate Ligament Reconstruction Procedures

An observational study in ACL Tears, sponsored by CONMED Corporation. Recruiting at 1 site in United States. Open to participants aged 14 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by CONMED Corporation · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
500
Ages
14 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 176 studies in Anterior Cruciate Ligament Injuries with a site in United States — 44 open to participants now, 62 under way, 3 of them phase 3. Anterior Cruciate Ligament Injuries · United States.

Planned enrollment
8th of 24
500 · median 202
Started
2025
with 8 others
Observational
24 of 176
6 open now
Primary completion
2030-06
later than 58 of 61 live
Registered
162nd of 176
by date

Among the 176 studies in Anterior Cruciate Ligament Injuries with a site in United States, this one is the 8th largest by planned enrollment of the 24 observational ones that give a count, is one of 9 that started in 2025, is one of 24 observational ones, reaches primary completion later than 58 of the 61 other live ones, and was the 162nd registered.

Anterior Cruciate Ligament Injuries

627 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 193 are open to participants now.

Browse Anterior Cruciate Ligament Injuries studies →

Open to participants now

44 of the 176 studies in Anterior Cruciate Ligament Injuries with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 122 Anterior Cruciate Ligament Injuries studies recruiting now, 27 (22%) set no upper age limit and 92 (75%) stop at 75 or younger; 46 take children under 18; 21 take healthy volunteers.

This study: 14 Years to 70 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies in Anterior Cruciate Ligament Injuries with a site in United States, or all of them as a file.
02

Study summary

This research study will evaluate mid-term clinical safety and performance outcomes of the BioBrace® Reinforced Implant when used to augment a tissue graft during anterior cruciate ligament (ACL) reconstruction.

Read the detailed description

This is a multi-center, single arm, open label registry investigating anterior cruciate ligament reconstruction (ACLR) procedures where the tissue graft is augmented with BioBrace®. Subjects meeting the inclusion/exclusion criteria will be enrolled retrospectively or prospectively. Clinical evaluations will be conducted at baseline (pre-operatively) and at 6 months, 1-, 2-, and 3-years post-operatively using various patient-reported outcome measures to assess pain, function, return to activity, and safety post-surgery.

03

Conditions studied

  • ACL Tears

Keywords

  • ACL reconstruction
  • BioBrace
  • augmentation
04

Who can participate

Ages eligible
14 Years to 70 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Community surrounding participating hospitals / clinics.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Underwent ACL reconstruction with a tissue graft augmented with BioBrace® within the past 24 months from study start date or scheduled to undergo ACL reconstruction with a tissue graft augmented with BioBrace®.
  2. Between 14 and 70 years old at the time of surgery.
  3. Can understand the content of the subject information / Form (ICF) for the prospective portion of the study.
  4. Is willing and able to participate in the prospective data collection protocol and comply with the required data collection.
  5. If the subject has already undergone ACLR within the past 24 months, subject must have at least two (2) of the following measures at baseline and 1 year post-operatively:

    1. International Knee Documentation Committee (IKDC)
    2. Knee Injury and Osteoarthritis Outcome Score Junior (KOOS, JR.)
    3. Patient-Reported Outcomes Measurement Information System (PROMIS-10)
    4. Tegner Activity Scale (TAS)
    5. Anterior Cruciate Ligament - Return to Sport After Injury (ACL-RSI)
  6. Positive diagnostic imaging by MRI at baseline indicating an ACL tear

Exclusion criteria

Exclusion Criteria:

  1. Has other concurrent medical or other conditions (chronic or acute in nature) that in the opinion of the participating investigator may prevent participation or otherwise render subject ineligible for the study.
  2. Is currently participating in an therapy (device and/or pharmaceutical) within 30 days prior to entering the study or such treatment is planned during the 3 years following enrollment into the study.
  3. Underwent or scheduled to undergo a multi-ligament reconstruction procedure (excluding cases where a torn MCL is treated non-operatively).
  4. Females of who are either pregnant or breastfeeding at the time of surgery.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • BioBrace Augment Group

    An anterior cruciate ligament reconstruction is performed and BioBrace is used to augment the tissue graft.

    Device: Anterior cruciate ligament reconstruction with BioBrace® augmentation · Procedure: Arthroscopic anterior cruciate ligament reconstruction

Interventions

  • DeviceAnterior cruciate ligament reconstruction with BioBrace® augmentation

    An arthroscopic anterior cruciate ligament reconstruction (ACLR) will be performed and the tissue graft will be augmented with the BioBrace® Reinforced Implant. BioBrace® is intended for use in surgical procedures for reinforcement of soft tissue where weakness exists. It is a bioresorbable, biocomposite scaffold composed of a highly porous collagen sponge and reinforced with poly-L-lactic-acid (PLLA). When used in ACLRs, it is sutured alongside the tissue graft to augment and reinforce the graft construct. BioBrace® is designed to mechanically and biologically augment weakened or torn soft tissue and can be integrated into surgeons' standard of care ACL reconstruction techniques.

  • ProcedureArthroscopic anterior cruciate ligament reconstruction

    An arthroscopic anterior cruciate ligament reconstruction is performed using standard surgical procedure.

06

What researchers measure

Primary outcomes

  1. Improvement in Function

    Improvement in function measured with International Knee Documentation Committee (IKDC) from baseline to 3 years post-surgery.

    Time frame: 3 years post-op

  2. Adverse Events

    Evaluation of device-related adverse events

    Time frame: Baseline, 6-months, 1-, 2-, and 3-years post-op

Secondary outcomes

  1. International Knee Documentation Committee (IKDC)

    Patient-reported functional and activity status as assessed by International Knee Documentation Committee (IKDC)

    Time frame: Baseline, 6 months, 1-, 2-years post-op

  2. Knee Injury and Osteoarthritis Outcome Score Junior (KOOS, JR.)

    Patient-reported functional and activity status as assessed by the following: Knee Injury and Osteoarthritis Outcome Score Junior (KOOS, JR.)

    Time frame: Baseline, 6 months, 1-, 2-, and 3-years post-op

  3. Patient-Reported Outcomes Measurement Information System (PROMIS-10)

    Patient-reported functional and activity status as assessed by the following: Patient-Reported Outcomes Measurement Information System (PROMIS-10)

    Time frame: Baseline, 6 months, 1-, 2-, and 3-years post-op

  4. Tegner Activity Scale (TAS)

    Patient-reported functional and activity status as assessed by: Tegner Activity Scale (TAS).

    Time frame: Baseline, 6 months, 1-, 2-, and 3-years post-op

  5. Anterior Cruciate Ligament - Return to Sport After Injury (ACL-RSI)

    Patient-reported functional and activity status as assessed by the following: Anterior Cruciate Ligament - Return to Sport After Injury (ACL-RSI)

    Time frame: 6 months, 1-, 2-, and 3-years post-op

  6. Secondary Surgical Intervention(s)

    The percentage of subjects who required additional surgical procedures following discharge from the BioBrace ACLR index procedure will be reported.

    Time frame: 6 months, 1-, 2-, and 3-years post-op

  7. Re-tear Rate

    Re-tear rate of the surgically reconstructed ACL tissue graft augmented with BioBrace. The percentage of subjects who experienced a re-tear of the augmented ACL tissue graft will be reported.

    Time frame: 6 months, 1-, 2-, and 3-years post-op

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jun 2030, 62 months after the start.

Of 82 observational studies under Anterior Cruciate Ligament Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 76. This study's planned 62 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2025
First posted
Apr 29, 2025
StartActual
Apr 8, 2025
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2030
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06948591
Lead sponsor
CONMED Corporation
Responsible party
Sponsor
First posted
Apr 29, 2025
Start date
Apr 8, 2025
Primary completion
Jun 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Oct 23, 2026

Study contacts

Kelley Grynewicz
Contact
ClinicalAffairs@conmed.com
7274574955

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion